NSE · GUJTHEM
Gujarat Themis Biosyn Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹152 Cr with net profit ₹49 Cr — a 31.99% net margin, versus 33.97% the period before.
Shareholding
As of 2026-06-30
- Promoter70.86%
- Public26.19%
- FII1.77%
- DII1.18%
27,010 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.13× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #1 of 15 by market cap · medians across 5 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Procter & Gamble Health Limited | ₹10,981 Cr | 116.08 | 20.94 | 62.32% | 23.22% |
| Medico Remedies Limited | ₹384 Cr | 65.15 | 5.06 | 17.38% | 6.36% |
| Par Drugs & Chemicals Ltd. | ₹118 Cr | 138.9 | 1.05 | 11.71% | 12.65% |
| Krebs Biochemicals & Industries Ltd. | ₹117 Cr | — | — | 10.4% | -71.34% |
| Ortin Global Limited | ₹12 Cr | — | 9.95 | -59.85% | -822.22% |
| Gujarat Themis Biosyn Ltd.(this company) | — | 356.9 | 13.52 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashGujarat Themis Biosyn Ltd. is listed on the Indian markets with a market capitalization of Rs 3966 Cr. The company reported a revenue of Rs 152.47 Cr and a profit margin of 28.14%. Its earnings per share (EPS) are Rs 4.28.
Positives
- +The debt-to-equity ratio is low at 0.07, indicating minimal reliance on borrowed capital.
- +The profit margin is 28.14%, showing efficient conversion of revenue into profit.
- +Promoter holding is substantial at 70.86% as of Mar 2026, indicating confidence in the company.
- +The company has a consistent dividend yield of 18%.
Negatives
- −Revenue declined by 12.58% from Rs 174.19 Cr in Mar 2024 to Rs 152.47 Cr in Mar 2025.
- −Net profit decreased by 17.56% from Rs 59.16 Cr in Mar 2024 to Rs 48.77 Cr in Mar 2025.
- −Earnings per share (EPS) fell significantly from Rs 40.72 in Mar 2024 to Rs 4.48 in Mar 2025.
- −A portion of promoter shares, specifically 5.44%, has been pledged as of Mar 2026.
- −The price-to-earnings (P/E) ratio is high at 363.95.
Financial Performance
The company's revenue increased from Rs 93.83 Cr in Mar 2021 to Rs 174.19 Cr in Mar 2024, before declining to Rs 152.47 Cr in Mar 2025. Net profit also showed an upward trend from Rs 30.18 Cr in Mar 2021 to Rs 59.16 Cr in Mar 2024, then decreased to Rs 48.77 Cr in Mar 2025. EPS followed a similar trajectory, rising from Rs 20.77 in Mar 2021 to Rs 40.72 in Mar 2024, and then falling to Rs 4.48 in Mar 2025.
Profitability & Returns
Gujarat Themis Biosyn Ltd. reported a return on equity (ROE) of 16.22% and a return on capital employed (ROCE) of 14.47%. The company’s profit margin stood at 28.14%. The earnings per share (EPS) for the latest period is Rs 4.28.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.07. Its book value per share is Rs 26.41. These figures indicate a strong financial structure with relatively low reliance on borrowed funds.
Ownership & Pledges
As of Mar 2026, promoters held 70.86% of the company's shares. Public shareholding was 26.16%, while FIIs held 1.80% and DIIs held 1.18%. Institutions collectively held 2.97% of the shares. A total of 5.44% of promoter shares were pledged, with Pharmaceutical Business Group [india] Ltd pledging 4.98% (2,550,000 shares) and Themis Medicare Limited pledging 6.53% (1,650,000 shares) of their respective holdings.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Gujarat Themis Biosyn Ltd.share price & fundamentals